Froedtert Hospital & Medical College of Wisconsin
Welcome,         Profile    Billing    Logout  
 29 Trials 
169 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shah, Nirav R
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
NCT06666491: An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

Recruiting
3
300
RoW
Tafenoquine, Primaquine, Chloroquine
GlaxoSmithKline
Malaria, Vivax
07/26
07/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2025 - Jun 2025 : Regulatory decisions in Japan related to approval for the treatment of Crohn's disease
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT04738279: The CASCADE HF Soft Launch and Calibration Phase I and II

Completed
2/3
20
US
Non-Invasive Continuous Remote Patient Monitoring, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
NorthShore University HealthSystem, physIQ, Inc., Carnegie Mellon University, Northwestern University
Heart Failure
10/21
10/21
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed
2/3
125
Canada, US
LAU-7b, fenretinide, Placebo oral capsule
Laurent Pharmaceuticals Inc.
COVID-19 Disease
02/24
05/24
BMT CTN CureAA, NCT06517641: Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

Recruiting
2
60
US
Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
Medical College of Wisconsin, National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Sanofi
Severe Aplastic Anemia
08/28
02/29
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
04/27
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Terminated
2
101
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
04/25
04/25
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Hourglass Jun 2025 - Jun 2025 : Updated data for r/r DLBCL
Active, not recruiting
1/2
206
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
NCT04283097: Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Completed
1
30
US
KPG-818, KPG-818 capsules
Kangpu Biopharmaceuticals, Ltd.
Hematological Malignancies
12/24
12/24
NCT05094206: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Terminated
1
4
US
0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells, 5x10^6 cells/kg CAR20.19.22 cells, Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
Medical College of Wisconsin, Miltenyi Biotec, Inc.
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia
01/24
01/24
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
120
US
Docirbrutinib, AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
SODA, NCT03771508: Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments

Active, not recruiting
N/A
8000
US
Medtronic - MITG
Small Intestine Disease, Small Intestine Cancer, Small Intestinal Ulcer Bleeding, Small Intestine Obstruction, Small Intestine Adenocarcinoma, Small Intestine Polyp
03/25
07/25
Connelly, Jennifer M
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
Chaudhary, Lubna
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
LYL797-101, NCT05274451: A Study to Investigate LYL797 in Adults With Solid Tumors

Terminated
1
57
US
LYL797
Lyell Immunopharma, Inc.
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
11/24
11/24
Coordinator, Site
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Completed
4
30
US
CREON, Pancrelipase
AbbVie
Cystic Fibrosis, Chronic Pancreatitis
07/23
08/23
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections

Completed
4
73
Europe, RoW
BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine
AbbVie
Facial Corrections, Facial Lines
10/23
10/23
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

Completed
4
52
US
Oxybutynin, Gelnique, Placebo
AbbVie
Overactive Detrusor, Neurogenic Bladder
08/23
10/23
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Completed
4
100
Canada, US
BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA
AbbVie
Upper Facial Lines
07/24
12/24
IMMpactful, NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Active, not recruiting
4
393
Europe, Canada, US, RoW
Risankizumab, Deucravacitinib
AbbVie
Moderate Plaque Psoriasis
12/25
03/26
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Active, not recruiting
4
214
US
Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab
AbbVie
Genital Psoriasis, Scalp Psoriasis
01/25
11/25
Flex-Up, NCT05507580 / 2022-000434-42: A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
4
461
Europe, Canada, Japan, RoW
Upadacitinib, RINVOQ, ABT-494
AbbVie, AbbVie Inc.
Atopic Dermatitis
07/24
08/24
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Active, not recruiting
3
112
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine
AbbVie, Roche-Genentech
Acute Myeloid Leukemia (AML)
09/22
06/26
NCT04994535 / 2021-000240-22: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Completed
3
426
Europe, Canada, US
OnabotulinumtoxinA, BOTOX, Placebo
AbbVie, AbbVie Inc.
Platysma Prominence
06/23
06/23
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Completed
3
1319
Canada, US
MR-100A-01, Transdermal contraceptive delivery system
Mylan Technologies Inc., Mylan Inc.
Contraception
01/25
01/25
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Completed
3
199
Europe, US, RoW
Dalbavancin, Xydalba, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
AbbVie
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
01/24
01/24
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants

Completed
3
140
RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Forehead Lines
09/24
09/24
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting
3
1095
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Genmab, AbbVie
Follicular Lymphoma (FL)
11/37
11/37
SELECT-GCA, NCT03725202 / 2017-003978-13: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Jan 2024 - Dec 2024: Regulatory submission for giant cell arteritis
Jan 2024 - Dec 2024: Data readout from SELECT-GCA trial for giant cell arteritis
Checkmark Initiation of P3 trial in giant cell arteritis
Feb 2019 - Feb 2019: Initiation of P3 trial in giant cell arteritis
Checkmark Trial initiation
More
Completed
3
438
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo
AbbVie
Giant Cell Arteritis (GCA)
02/24
02/25
ECLIPSE, NCT06241313: Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

Recruiting
3
1300
Europe, Japan, RoW
Atogepant, Qulipta, Aquipta, Placebo for Atogepant
AbbVie
Migraine
09/25
11/25
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Completed
3
286
Europe, Canada, US, RoW
Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret
AbbVie
Hepatitis C Virus (HCV)
09/24
09/24
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
3
920
Europe, Canada, Japan, US, RoW
Dupilumab, Dupixent®, Upadacitinib, ABT-494, RINVOQ
AbbVie, AbbVie Inc.
Atopic Dermatitis
03/24
08/24
NCT06387394: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence

Active, not recruiting
3
202
US
BOTOX, OnabotulinumtoxinA, Placebo
AbbVie
Masseter Muscle Prominence
12/25
12/25
NCT06158841: Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
380
Europe, Canada, Japan, US, RoW
Etentamig, ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
AbbVie
Multiple Myeloma
12/27
12/27
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Recruiting
3
300
Canada, Japan, US, RoW
Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B
AbbVie
Atopic Dermatitis
08/26
03/27
NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
1280
Europe, Canada, Japan, US, RoW
Lutikizumab, ABT-981, Placebo
AbbVie
Hidradenitis Suppurativa
12/26
12/26
NCT05028569 / 2021-001979-16: Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Hourglass Jan 2023 - Dec 2023 : Data from trial for episodic migraine
Completed
3
775
Europe, Canada, US, RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Episodic Migraine
11/24
11/24
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Recruiting
3
120
Europe, US, RoW
Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab
AbbVie
Chronic Lymphocytic Leukemia
12/26
12/26
EPCORE DLBCL-4, NCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/28
01/28
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Hourglass Jan 2024 - Dec 2024 : Data readout from P3 TRANSFORM-2 trial in combination with ruxolitinib for r/r myelofibrosis
Hourglass Jan 2024 - Dec 2024 : Regulatory submission for r/r myelofibrosis (based on TRANSFORM-2 trial)
Active, not recruiting
3
330
Europe, Canada, Japan, US, RoW
Navitoclax, Ruxolitinib, Best Available Therapy (BAT)
AbbVie
Myelofibrosis (MF)
01/25
12/26
Start Up, NCT06461897: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Recruiting
3
675
Europe, Canada, US, RoW
Upadacitinib, ABT-494, RINVOQ®, RINVOQ LQ, Dupilumab
AbbVie
Atopic Dermatitis
07/30
07/30
UBRO MM, NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting
3
450
US
Ubrogepant, UBRELVY, Placebo for Ubrogepant
AbbVie
Migraine
06/27
09/27
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Not yet recruiting
3
80
US
Mesalamine, Delzicol, Placebo
AbbVie
Ulcerative Colitis (UC)
07/26
07/26
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

Completed
3
438
Europe, Canada, US, RoW
Linaclotide, Placebo
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation, Irritable Bowel Syndrome With Constipation
05/24
05/24
OptIMMize-1, NCT04435600 / 2019-004141-32: A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Completed
3
139
Europe, Canada, Japan, US
Risankizumab, SKYRIZI, ABBV-066, Ustekinumab
AbbVie
Psoriasis
02/24
10/24
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

Completed
3
161
US
Cariprazine, VRAYLAR, AGN-241780, Placebo
AbbVie
Autism Spectrum Disorder
10/24
10/24
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Active, not recruiting
3
123
Europe, US
Linaclotide, Placebo for Linaclotide
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
09/25
09/25
ELARIS EM-COC, NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Recruiting
3
800
US
Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive
AbbVie
Endometriosis
03/29
06/30
NCT06612151: A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Recruiting
3
438
RoW
YL201, topotecan hydrochloride for injection
MediLink Therapeutics (Suzhou) Co., Ltd.
Small Cell Lung Cancer
12/27
12/30
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Completed
3
75
US
Atogepant, QULIPTA
AbbVie
Chronic Migraine
05/25
05/25
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants

Completed
3
159
US
VOLITE XC, JUVÉDERM® VOLITE™ XC
AbbVie
Neck Lines
09/24
09/24
NCT06629597: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting
3
400
RoW
YL201, Docetaxel, Capecitabine, Gemcitabine
MediLink Therapeutics (Suzhou) Co., Ltd.
Nasopharyngeal Carcinoma
12/27
12/28
NCT06806293: Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting
3
430
Europe, Japan, RoW
Atogepant, Qulipta, Aquipta, Placebo for Atogepant
AbbVie
Menstrual Migraine (MM)
02/27
07/27
NCT06822738: A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

Recruiting
3
130
US
XEN63 Glaucoma Treatment System
AbbVie
Primary Open Angle Glaucoma
11/28
11/28
NCT06810505: A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Recruiting
3
420
Europe, Canada, Japan, US
Atogepant, Qulipta, Aquipta, Placebo for Atogepant
AbbVie
Chronic Migraine
03/31
03/31
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

Completed
3
171
Europe, Canada
HArmonyCa Lidocaine Injectable Gel
Allergan
Mid Face Volume Deficit
05/25
05/25
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Active, not recruiting
3
1399
Europe, Canada, Japan, US, RoW
Upadacitinib, Rinvoq, ABT-494, Placebo
AbbVie
Alopecia Areata
01/28
01/28
TeliMET NSCLC-01, NCT04928846 / 2021-001811-94: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
698
Europe, Canada, Japan, US, RoW
Telisotuzumab Vedotin, ABBV-399, Docetaxel
AbbVie
Non Small Cell Lung Cancer
03/28
03/28
REVAMP, NCT06880744: A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

Recruiting
3
530
Europe, Canada, US
Risankizumab, Vedolizumab
AbbVie
Ulcerative Colitis
09/28
09/28
NCT05995340: ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars

Active, not recruiting
3
157
Europe, Canada
ELAPR002f Injectable Gel, Saline Active Control
AbbVie
Atrophic Acne Scars
08/26
08/26
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Active, not recruiting
3
310
US
Cariprazine Flexible Dose
AbbVie
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
09/25
09/25
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
NCT03850782 / 2018-002574-52: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Active, not recruiting
3
515
Europe, US, RoW
Bimatoprost (SR)
AbbVie
Open-Angle Glaucoma, Ocular Hypertension
08/25
08/25
NCT05411198: Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

Recruiting
3
65
US, RoW
XEN45 (Glaucoma Gel Stent)
AbbVie
Open-Angle Glaucoma
08/25
08/25
SELECT- SWITCH, NCT05814627: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
487
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Adalimumab, Humira, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
AbbVie
Rheumatoid Arthritis
08/25
08/26
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Active, not recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
Step-Up HS, NCT05889182: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Recruiting
3
1328
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Placebo
AbbVie
Hidradenitis Suppurativa
03/28
03/28
CANOVA, NCT03539744 / 2017-003838-88: A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Jan 2023 - Jun 2023: Data from CANOVA trial for r/r multiple myeloma
Active, not recruiting
3
265
Europe, Canada, Japan, US, RoW
Pomalidomide, Pomalyst, Dexamethasone, Venetoclax, ABT-199, GDC-0199
AbbVie, Roche-Genentech
Multiple Myeloma
08/26
11/27
NCT06063967: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Recruiting
3
276
Europe, Canada, Japan, US, RoW
Risankizumab SC, ABBV-066, SKYRIZI, Placebo for risankizumab
AbbVie
Crohn's Disease
07/27
02/29
NCT05125302: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Recruiting
3
1059
US
Ubrogepant, Ubrelvy, Placebo-Matching Ubrogepant
AbbVie
Migraine
05/26
05/26
TEMPLE, NCT05748483: Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

Active, not recruiting
3
545
Europe, Canada, RoW
Atogepant, QULIPTA, Placebo for Atogepant, Topiramate, Placebo for Topiramate
AbbVie
Migraine
04/25
05/26
NCT04064827: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Recruiting
3
16
US
Paricalcitol
AbbVie
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
06/26
10/26
NCT06100744: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Recruiting
3
40
Europe, Canada, US, RoW
Adalimumab, Risankizumab, ABBV-066, Skyrizi
AbbVie
Juvenile Psoriatic Arthritis
09/26
10/28
SELECT-SLE, NCT05843643: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Placebo
AbbVie
Systemic Lupus Erythematosus
12/26
10/27
VIALE-T, NCT04161885 / 2019-002621-30: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

Active, not recruiting
3
465
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, VENCLEXTA, Azacitidine, Best Supportive Care (BSC)
AbbVie
Acute Myeloid Leukemia (AML), Cancer
04/25
11/26
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
3
900
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
06/27
12/29
NCT05609630: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Recruiting
3
90
Europe, Japan, US, RoW
Upadacitinib, RINVOQ, ABT-494, Tocilizumab
AbbVie
Juvenile Idiopathic Arthritis
06/29
06/29
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Recruiting
3
250
Europe, US, RoW
Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu®
Daiichi Sankyo, AstraZeneca
Breast Cancer
10/27
10/27
NCT05711394: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Recruiting
3
450
Europe, Canada, Japan, US, RoW
Atogepant, QULIPTA, AGN-241689, Placebo-Matching Atogepant
AbbVie
Episodic Migraine
03/28
05/28
U-ASTOUND, NCT05782907: Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Recruiting
3
110
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ
AbbVie
Ulcerative Colitis
08/28
10/33
RISE, NCT05995353: A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Recruiting
3
110
Europe, Canada, Japan, US, RoW
Risankizumab, ABBV-066, SKYRIZI
AbbVie
Crohn's Disease
04/29
04/29
NCT05707949: Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

Enrolling by invitation
3
650
Europe, Canada, Japan, US, RoW
Atogepant, QULIPTA, AGN-241689
AbbVie
Migraine Prophylaxis
11/29
11/29
EPCORE FL-1, NCT05409066 / 2021-000169-34: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Active, not recruiting
3
549
Europe, Canada, Japan, US, RoW
Epcoritamab, Rituximab, Lenalidomide
Genmab, AbbVie
Follicular Lymphoma (FL)
10/30
10/30
LIVIGNO-4, NCT06236438: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2/3
840
Europe, Japan, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
AbbVie
Non-Small Cell Lung Cancer
10/31
10/31
NCT06345339: A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Recruiting
2/3
2800
US
Armour Thyroid, AGN-282176, Levothyroxine, Synthetic T4
AbbVie
Hypothyroidism
09/27
06/28
LIVIGNO-2, NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Active, not recruiting
2/3
660
Europe, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab
AbbVie
Hepatocellular Carcinoma
09/30
09/30
NCT04853368 / 2020-005805-25: Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Hourglass Sep 2021 - Dec 2021 : Data from trial in combination with Navocaftor and ABBV-119 for cystic fibrosis
Terminated
2
48
Europe, US, RoW
ABBV-576, Galicaftor, ABBV-2222, Placebo, Navocaftor, ABBV-3067, ABBV-119
AbbVie
Cystic Fibrosis (CF)
06/23
06/23
AIM-CD, NCT05068284 / 2021-002869-18: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

Hourglass Jan 2024 - Dec 2024 : Data for Crohn’s disease
Terminated
2
176
Europe, Canada, Japan, US, RoW
ABBV-154, Placebo
AbbVie, AbbVie Inc., Abbvie Inc.
Crohn's Disease
07/23
07/23
NCT03339128 / 2017-003770-14: Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

Recruiting
2
95
Europe, Canada, US
Eluxadoline, Viberzi, Placebo
AbbVie
Irritable Bowel Syndrome
12/26
12/26
NCT06151535: A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants

Completed
2
30
Europe
ELAPR002f Injectable Gel
AbbVie
Skin Quality Deficit
02/25
02/25
NCT06241846: A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Recruiting
2
100
RoW
YL201 for Injection
MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Castration-resistant Prostate Cancer (mCRPC)
02/27
02/29
NCT06257875: A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

Recruiting
2
200
Europe, Canada, Japan, US, RoW
Lutikizumab Matching Placebo, Adalimumab Matching Placebo, Lutikizumab, ABT-981, Adalimumab, Humira
AbbVie
Ulcerative Colitis
04/28
04/28
NCT05760313: A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Completed
2
19
Europe, US, RoW
Linaclotide, Linzess, Placebo
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation
06/25
06/25
NCT05141006: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Completed
2
83
Canada, US
BOTOX, OnabotulinumtoxinA, Botulinum Toxin Type A, Placebo for BOTOX
AbbVie
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
07/24
12/24
IDeate-Lung01, NCT05280470 / 2022-000503-13: Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Active, not recruiting
2
187
Europe, Japan, US, RoW
Ifinatamab Deruxtecan (I-DXd), DS-7300a
Daiichi Sankyo, Merck Sharp & Dohme LLC
Extensive-stage Small-cell Lung Cancer
03/25
11/25
NCT05771428: Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

Completed
2
263
Europe, Japan, US, RoW
ABBV-552, Placebo for ABBV-552
AbbVie
Alzheimer's Disease (AD)
08/24
09/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shah, Nirav R
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
NCT06666491: An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

Recruiting
3
300
RoW
Tafenoquine, Primaquine, Chloroquine
GlaxoSmithKline
Malaria, Vivax
07/26
07/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2025 - Jun 2025 : Regulatory decisions in Japan related to approval for the treatment of Crohn's disease
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT04738279: The CASCADE HF Soft Launch and Calibration Phase I and II

Completed
2/3
20
US
Non-Invasive Continuous Remote Patient Monitoring, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
NorthShore University HealthSystem, physIQ, Inc., Carnegie Mellon University, Northwestern University
Heart Failure
10/21
10/21
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed
2/3
125
Canada, US
LAU-7b, fenretinide, Placebo oral capsule
Laurent Pharmaceuticals Inc.
COVID-19 Disease
02/24
05/24
BMT CTN CureAA, NCT06517641: Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

Recruiting
2
60
US
Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
Medical College of Wisconsin, National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Sanofi
Severe Aplastic Anemia
08/28
02/29
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
04/27
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Terminated
2
101
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
04/25
04/25
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Hourglass Jun 2025 - Jun 2025 : Updated data for r/r DLBCL
Active, not recruiting
1/2
206
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
NCT04283097: Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Completed
1
30
US
KPG-818, KPG-818 capsules
Kangpu Biopharmaceuticals, Ltd.
Hematological Malignancies
12/24
12/24
NCT05094206: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Terminated
1
4
US
0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells, 5x10^6 cells/kg CAR20.19.22 cells, Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
Medical College of Wisconsin, Miltenyi Biotec, Inc.
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia
01/24
01/24
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
120
US
Docirbrutinib, AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
SODA, NCT03771508: Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments

Active, not recruiting
N/A
8000
US
Medtronic - MITG
Small Intestine Disease, Small Intestine Cancer, Small Intestinal Ulcer Bleeding, Small Intestine Obstruction, Small Intestine Adenocarcinoma, Small Intestine Polyp
03/25
07/25
Connelly, Jennifer M
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
Chaudhary, Lubna
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
LYL797-101, NCT05274451: A Study to Investigate LYL797 in Adults With Solid Tumors

Terminated
1
57
US
LYL797
Lyell Immunopharma, Inc.
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
11/24
11/24
Coordinator, Site
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Completed
4
30
US
CREON, Pancrelipase
AbbVie
Cystic Fibrosis, Chronic Pancreatitis
07/23
08/23
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections

Completed
4
73
Europe, RoW
BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine
AbbVie
Facial Corrections, Facial Lines
10/23
10/23
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

Completed
4
52
US
Oxybutynin, Gelnique, Placebo
AbbVie
Overactive Detrusor, Neurogenic Bladder
08/23
10/23
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Completed
4
100
Canada, US
BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA
AbbVie
Upper Facial Lines
07/24
12/24
IMMpactful, NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Active, not recruiting
4
393
Europe, Canada, US, RoW
Risankizumab, Deucravacitinib
AbbVie
Moderate Plaque Psoriasis
12/25
03/26
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Active, not recruiting
4
214
US
Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab
AbbVie
Genital Psoriasis, Scalp Psoriasis
01/25
11/25
Flex-Up, NCT05507580 / 2022-000434-42: A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
4
461
Europe, Canada, Japan, RoW
Upadacitinib, RINVOQ, ABT-494
AbbVie, AbbVie Inc.
Atopic Dermatitis
07/24
08/24
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Active, not recruiting
3
112
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine
AbbVie, Roche-Genentech
Acute Myeloid Leukemia (AML)
09/22
06/26
NCT04994535 / 2021-000240-22: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Completed
3
426
Europe, Canada, US
OnabotulinumtoxinA, BOTOX, Placebo
AbbVie, AbbVie Inc.
Platysma Prominence
06/23
06/23
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Completed
3
1319
Canada, US
MR-100A-01, Transdermal contraceptive delivery system
Mylan Technologies Inc., Mylan Inc.
Contraception
01/25
01/25
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Completed
3
199
Europe, US, RoW
Dalbavancin, Xydalba, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
AbbVie
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
01/24
01/24
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants

Completed
3
140
RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Forehead Lines
09/24
09/24
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting
3
1095
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Genmab, AbbVie
Follicular Lymphoma (FL)
11/37
11/37
SELECT-GCA, NCT03725202 / 2017-003978-13: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Jan 2024 - Dec 2024: Regulatory submission for giant cell arteritis
Jan 2024 - Dec 2024: Data readout from SELECT-GCA trial for giant cell arteritis
Checkmark Initiation of P3 trial in giant cell arteritis
Feb 2019 - Feb 2019: Initiation of P3 trial in giant cell arteritis
Checkmark Trial initiation
More
Completed
3
438
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo
AbbVie
Giant Cell Arteritis (GCA)
02/24
02/25
ECLIPSE, NCT06241313: Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

Recruiting
3
1300
Europe, Japan, RoW
Atogepant, Qulipta, Aquipta, Placebo for Atogepant
AbbVie
Migraine
09/25
11/25
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Completed
3
286
Europe, Canada, US, RoW
Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret
AbbVie
Hepatitis C Virus (HCV)
09/24
09/24
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
3
920
Europe, Canada, Japan, US, RoW
Dupilumab, Dupixent®, Upadacitinib, ABT-494, RINVOQ
AbbVie, AbbVie Inc.
Atopic Dermatitis
03/24
08/24
NCT06387394: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence

Active, not recruiting
3
202
US
BOTOX, OnabotulinumtoxinA, Placebo
AbbVie
Masseter Muscle Prominence
12/25
12/25
NCT06158841: Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
380
Europe, Canada, Japan, US, RoW
Etentamig, ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
AbbVie
Multiple Myeloma
12/27
12/27
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Recruiting
3
300
Canada, Japan, US, RoW
Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B
AbbVie
Atopic Dermatitis
08/26
03/27
NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
1280
Europe, Canada, Japan, US, RoW
Lutikizumab, ABT-981, Placebo
AbbVie
Hidradenitis Suppurativa
12/26
12/26
NCT05028569 / 2021-001979-16: Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Hourglass Jan 2023 - Dec 2023 : Data from trial for episodic migraine
Completed
3
775
Europe, Canada, US, RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Episodic Migraine
11/24
11/24
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Recruiting
3
120
Europe, US, RoW
Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab
AbbVie
Chronic Lymphocytic Leukemia
12/26
12/26
EPCORE DLBCL-4, NCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/28
01/28
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Hourglass Jan 2024 - Dec 2024 : Data readout from P3 TRANSFORM-2 trial in combination with ruxolitinib for r/r myelofibrosis
Hourglass Jan 2024 - Dec 2024 : Regulatory submission for r/r myelofibrosis (based on TRANSFORM-2 trial)
Active, not recruiting
3
330
Europe, Canada, Japan, US, RoW
Navitoclax, Ruxolitinib, Best Available Therapy (BAT)
AbbVie
Myelofibrosis (MF)
01/25
12/26
Start Up, NCT06461897: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Recruiting
3
675
Europe, Canada, US, RoW
Upadacitinib, ABT-494, RINVOQ®, RINVOQ LQ, Dupilumab
AbbVie
Atopic Dermatitis
07/30
07/30
UBRO MM, NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting
3
450
US
Ubrogepant, UBRELVY, Placebo for Ubrogepant
AbbVie
Migraine
06/27
09/27
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Not yet recruiting
3
80
US
Mesalamine, Delzicol, Placebo
AbbVie
Ulcerative Colitis (UC)
07/26
07/26
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

Completed
3
438
Europe, Canada, US, RoW
Linaclotide, Placebo
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation, Irritable Bowel Syndrome With Constipation
05/24
05/24
OptIMMize-1, NCT04435600 / 2019-004141-32: A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Completed
3
139
Europe, Canada, Japan, US
Risankizumab, SKYRIZI, ABBV-066, Ustekinumab
AbbVie
Psoriasis
02/24
10/24
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

Completed
3
161
US
Cariprazine, VRAYLAR, AGN-241780, Placebo
AbbVie
Autism Spectrum Disorder
10/24
10/24
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Active, not recruiting
3
123
Europe, US
Linaclotide, Placebo for Linaclotide
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
09/25
09/25
ELARIS EM-COC, NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Recruiting
3
800
US
Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive
AbbVie
Endometriosis
03/29
06/30
NCT06612151: A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Recruiting
3
438
RoW
YL201, topotecan hydrochloride for injection
MediLink Therapeutics (Suzhou) Co., Ltd.
Small Cell Lung Cancer
12/27
12/30
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Completed
3
75
US
Atogepant, QULIPTA
AbbVie
Chronic Migraine
05/25
05/25
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants

Completed
3
159
US
VOLITE XC, JUVÉDERM® VOLITE™ XC
AbbVie
Neck Lines
09/24
09/24
NCT06629597: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting
3
400
RoW
YL201, Docetaxel, Capecitabine, Gemcitabine
MediLink Therapeutics (Suzhou) Co., Ltd.
Nasopharyngeal Carcinoma
12/27
12/28
NCT06806293: Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting
3
430
Europe, Japan, RoW
Atogepant, Qulipta, Aquipta, Placebo for Atogepant
AbbVie
Menstrual Migraine (MM)
02/27
07/27
NCT06822738: A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

Recruiting
3
130
US
XEN63 Glaucoma Treatment System
AbbVie
Primary Open Angle Glaucoma
11/28
11/28
NCT06810505: A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Recruiting
3
420
Europe, Canada, Japan, US
Atogepant, Qulipta, Aquipta, Placebo for Atogepant
AbbVie
Chronic Migraine
03/31
03/31
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

Completed
3
171
Europe, Canada
HArmonyCa Lidocaine Injectable Gel
Allergan
Mid Face Volume Deficit
05/25
05/25
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Active, not recruiting
3
1399
Europe, Canada, Japan, US, RoW
Upadacitinib, Rinvoq, ABT-494, Placebo
AbbVie
Alopecia Areata
01/28
01/28
TeliMET NSCLC-01, NCT04928846 / 2021-001811-94: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
698
Europe, Canada, Japan, US, RoW
Telisotuzumab Vedotin, ABBV-399, Docetaxel
AbbVie
Non Small Cell Lung Cancer
03/28
03/28
REVAMP, NCT06880744: A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

Recruiting
3
530
Europe, Canada, US
Risankizumab, Vedolizumab
AbbVie
Ulcerative Colitis
09/28
09/28
NCT05995340: ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars

Active, not recruiting
3
157
Europe, Canada
ELAPR002f Injectable Gel, Saline Active Control
AbbVie
Atrophic Acne Scars
08/26
08/26
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Active, not recruiting
3
310
US
Cariprazine Flexible Dose
AbbVie
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
09/25
09/25
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
NCT03850782 / 2018-002574-52: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Active, not recruiting
3
515
Europe, US, RoW
Bimatoprost (SR)
AbbVie
Open-Angle Glaucoma, Ocular Hypertension
08/25
08/25
NCT05411198: Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

Recruiting
3
65
US, RoW
XEN45 (Glaucoma Gel Stent)
AbbVie
Open-Angle Glaucoma
08/25
08/25
SELECT- SWITCH, NCT05814627: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
487
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Adalimumab, Humira, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
AbbVie
Rheumatoid Arthritis
08/25
08/26
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Active, not recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
Step-Up HS, NCT05889182: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Recruiting
3
1328
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Placebo
AbbVie
Hidradenitis Suppurativa
03/28
03/28
CANOVA, NCT03539744 / 2017-003838-88: A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Jan 2023 - Jun 2023: Data from CANOVA trial for r/r multiple myeloma
Active, not recruiting
3
265
Europe, Canada, Japan, US, RoW
Pomalidomide, Pomalyst, Dexamethasone, Venetoclax, ABT-199, GDC-0199
AbbVie, Roche-Genentech
Multiple Myeloma
08/26
11/27
NCT06063967: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Recruiting
3
276
Europe, Canada, Japan, US, RoW
Risankizumab SC, ABBV-066, SKYRIZI, Placebo for risankizumab
AbbVie
Crohn's Disease
07/27
02/29
NCT05125302: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Recruiting
3
1059
US
Ubrogepant, Ubrelvy, Placebo-Matching Ubrogepant
AbbVie
Migraine
05/26
05/26
TEMPLE, NCT05748483: Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

Active, not recruiting
3
545
Europe, Canada, RoW
Atogepant, QULIPTA, Placebo for Atogepant, Topiramate, Placebo for Topiramate
AbbVie
Migraine
04/25
05/26
NCT04064827: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Recruiting
3
16
US
Paricalcitol
AbbVie
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
06/26
10/26
NCT06100744: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Recruiting
3
40
Europe, Canada, US, RoW
Adalimumab, Risankizumab, ABBV-066, Skyrizi
AbbVie
Juvenile Psoriatic Arthritis
09/26
10/28
SELECT-SLE, NCT05843643: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Placebo
AbbVie
Systemic Lupus Erythematosus
12/26
10/27
VIALE-T, NCT04161885 / 2019-002621-30: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

Active, not recruiting
3
465
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, VENCLEXTA, Azacitidine, Best Supportive Care (BSC)
AbbVie
Acute Myeloid Leukemia (AML), Cancer
04/25
11/26
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
3
900
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
06/27
12/29
NCT05609630: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Recruiting
3
90
Europe, Japan, US, RoW
Upadacitinib, RINVOQ, ABT-494, Tocilizumab
AbbVie
Juvenile Idiopathic Arthritis
06/29
06/29
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Recruiting
3
250
Europe, US, RoW
Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu®
Daiichi Sankyo, AstraZeneca
Breast Cancer
10/27
10/27
NCT05711394: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Recruiting
3
450
Europe, Canada, Japan, US, RoW
Atogepant, QULIPTA, AGN-241689, Placebo-Matching Atogepant
AbbVie
Episodic Migraine
03/28
05/28
U-ASTOUND, NCT05782907: Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Recruiting
3
110
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ
AbbVie
Ulcerative Colitis
08/28
10/33
RISE, NCT05995353: A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Recruiting
3
110
Europe, Canada, Japan, US, RoW
Risankizumab, ABBV-066, SKYRIZI
AbbVie
Crohn's Disease
04/29
04/29
NCT05707949: Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

Enrolling by invitation
3
650
Europe, Canada, Japan, US, RoW
Atogepant, QULIPTA, AGN-241689
AbbVie
Migraine Prophylaxis
11/29
11/29
EPCORE FL-1, NCT05409066 / 2021-000169-34: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Active, not recruiting
3
549
Europe, Canada, Japan, US, RoW
Epcoritamab, Rituximab, Lenalidomide
Genmab, AbbVie
Follicular Lymphoma (FL)
10/30
10/30
LIVIGNO-4, NCT06236438: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2/3
840
Europe, Japan, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
AbbVie
Non-Small Cell Lung Cancer
10/31
10/31
NCT06345339: A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Recruiting
2/3
2800
US
Armour Thyroid, AGN-282176, Levothyroxine, Synthetic T4
AbbVie
Hypothyroidism
09/27
06/28
LIVIGNO-2, NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Active, not recruiting
2/3
660
Europe, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab
AbbVie
Hepatocellular Carcinoma
09/30
09/30
NCT04853368 / 2020-005805-25: Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Hourglass Sep 2021 - Dec 2021 : Data from trial in combination with Navocaftor and ABBV-119 for cystic fibrosis
Terminated
2
48
Europe, US, RoW
ABBV-576, Galicaftor, ABBV-2222, Placebo, Navocaftor, ABBV-3067, ABBV-119
AbbVie
Cystic Fibrosis (CF)
06/23
06/23
AIM-CD, NCT05068284 / 2021-002869-18: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

Hourglass Jan 2024 - Dec 2024 : Data for Crohn’s disease
Terminated
2
176
Europe, Canada, Japan, US, RoW
ABBV-154, Placebo
AbbVie, AbbVie Inc., Abbvie Inc.
Crohn's Disease
07/23
07/23
NCT03339128 / 2017-003770-14: Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

Recruiting
2
95
Europe, Canada, US
Eluxadoline, Viberzi, Placebo
AbbVie
Irritable Bowel Syndrome
12/26
12/26
NCT06151535: A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants

Completed
2
30
Europe
ELAPR002f Injectable Gel
AbbVie
Skin Quality Deficit
02/25
02/25
NCT06241846: A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Recruiting
2
100
RoW
YL201 for Injection
MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Castration-resistant Prostate Cancer (mCRPC)
02/27
02/29
NCT06257875: A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

Recruiting
2
200
Europe, Canada, Japan, US, RoW
Lutikizumab Matching Placebo, Adalimumab Matching Placebo, Lutikizumab, ABT-981, Adalimumab, Humira
AbbVie
Ulcerative Colitis
04/28
04/28
NCT05760313: A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Completed
2
19
Europe, US, RoW
Linaclotide, Linzess, Placebo
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation
06/25
06/25
NCT05141006: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Completed
2
83
Canada, US
BOTOX, OnabotulinumtoxinA, Botulinum Toxin Type A, Placebo for BOTOX
AbbVie
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
07/24
12/24
IDeate-Lung01, NCT05280470 / 2022-000503-13: Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Active, not recruiting
2
187
Europe, Japan, US, RoW
Ifinatamab Deruxtecan (I-DXd), DS-7300a
Daiichi Sankyo, Merck Sharp & Dohme LLC
Extensive-stage Small-cell Lung Cancer
03/25
11/25
NCT05771428: Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

Completed
2
263
Europe, Japan, US, RoW
ABBV-552, Placebo for ABBV-552
AbbVie
Alzheimer's Disease (AD)
08/24
09/24
 

Download Options